Research programme: antibacterials - GPC Biotech

Drug Profile

Research programme: antibacterials - GPC Biotech

Alternative Names: Antibacterials research programme - GPC Biotech

Latest Information Update: 10 May 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GPC Biotech AG
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 10 May 2004 This antibacterials research programme is available for licensing (
  • 31 Dec 2003 The licensing agreement between GPC Biotech and PanTherix has been terminated
  • 31 Dec 2003 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top